\n
\n
\n Date
\n Event
\n Sentiment
\n Move
\n Catalyst
\n
\n
\n
\n
\n
\n Jan 30
\n
\n
\n Pipeline expansion<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n +4.3%
\n
\n
\n
\n Peer-reviewed case series supported potential expansion of exosome therapy pipeline.
\n
\n
\n
\n
\n Jan 08
\n
\n
\n Executive appointment<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n +2.0%
\n
\n
\n
\n Appointment of experienced CFO to lead financial strategy and controls.
\n
\n
\n
\n
\n Oct 31
\n
\n
\n Business combination<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n +15800.6%
\n
\n
\n
\n Closing of Globalink business combination and start of Nasdaq trading.
\n
\n
\n
\n <\/p>\n
Pattern Detected<\/p>\n
Recent company announcements, including pipeline and corporate milestones, were followed by positive price reactions.<\/p>\n
Recent Company History<\/p>\n
Over the past several months, Alps Group moved from a SPAC business combination to building visibility around its biotech platform. The closing of the Globalink deal on Oct 31, 2025 and Nasdaq listing produced a sharp positive move. Subsequent news on potential exosome pipeline expansion on Jan 30, 2026 and the CFO appointment on Jan 8, 2026 also saw positive reactions. Today\u2019s autologous NK cell safety and tolerability data fits a pattern of early-stage clinical validation updates following the combination.<\/p>\n
\n This announcement adds peer-reviewed safety and tolerability data from a nine-patient autologous NK cell case series, reinforcing Alps Group\u2019s focus on next-generation cell therapies. The publication complements earlier disclosures that its pipeline remains preclinical and that recent losses reached $66.2 million. Investors may watch for larger, controlled studies, regulatory interactions, and how future financings are managed as the company scales its in-house culture protocol toward broader clinical development.
\n <\/p>\n
\n
\n autologous
\n
\n medical
\n
\n
<\/p>\n
“findings from nine patients who received autologous Natural Killer (NK) cell infusions”<\/p>\n
Autologous describes a medical product or treatment made from a patient\u2019s own cells or tissues rather than from a donor. For investors, autologous approaches matter because they can lower the risk of immune rejection and improve effectiveness, but they often require individualized manufacturing, complex logistics, and higher per-patient costs\u2014factors that affect scalability, pricing, and regulatory hurdles in healthcare businesses.<\/p>\n
<\/p>\n
\n
\n natural killer (nk) cells
\n
\n medical
\n
\n
<\/p>\n
“Natural Killer (NK) cells are a type of immune cell involved in the body\u2019s natural defense”<\/p>\n
Natural killer (NK) cells are a type of white blood cell that act like the immune system\u2019s security guards, spotting and destroying infected or abnormal cells without needing prior training. For investors, NK cells matter because they are central to many drug and diagnostic programs\u2014especially in cancer and infectious disease\u2014affecting trial results, regulatory decisions, manufacturing complexity and the commercial potential of therapies that boost or use these cells.<\/p>\n
<\/p>\n
\n
\n good clinical practice
\n
\n regulatory
\n
\n
<\/p>\n
“in accordance with the ethical principles of the Declaration of Helsinki and Malaysian Good Clinical Practice guidelines”<\/p>\n
Good clinical practice is a global set of ethical and scientific rules for designing, conducting, recording, and reporting clinical trials so that participant safety is protected and results are reliable. For investors, adherence to these rules is like following a strict recipe and inspection checklist: it reduces the risk that trial data will be rejected by regulators, delays approval, or causes costly rework, and therefore affects a company\u2019s timeline, costs, and credibility.<\/p>\n
<\/p>\n
\n
\n cytotoxicity
\n
\n medical
\n
\n
<\/p>\n
“The NK cells also exhibited cytotoxicity toward in vitro cultured and co-incubated cancer cell models”<\/p>\n
Cytotoxicity is the ability of a substance to kill or damage living cells. Investors watch cytotoxicity results because they indicate whether a drug or chemical is likely to be effective against targeted cells (for example, cancer cells) and whether it poses safety risks to healthy tissue, which affects clinical success, regulatory approval, and commercial potential\u2014similar to knowing if a powerful weed killer also harms the lawn around the weeds.<\/p>\n
<\/p>\n
\n
\n immunotherapy
\n
\n medical
\n
\n
<\/p>\n
“potentially making advanced immunotherapy more accessible and efficient”<\/p>\n
Treatment that uses or enhances the body\u2019s immune system to detect and fight disease, most often cancers or chronic infections; think of it as training or arming the body\u2019s own soldiers to find and destroy targets. It matters to investors because successful immunotherapies can lead to high-value drug approvals, recurring revenue from long-term treatments, and changes in competitive dynamics, while failures or safety issues in clinical trials can materially affect company valuations.<\/p>\n
<\/p>\n
AI-generated analysis. Not financial advice.<\/p>\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n 02\/23\/2026 – 08:00 AM
\n
\n
<\/p>\n
KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) — Alps Group Inc (the \u201cCompany\u201d or \u201cAlps Group\u201d), the parent company of Alps Life Sciences Inc. (\u201cAlps Holdco\u201d), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced a peer-reviewed case study in the February 2026 edition of SAGE Open Medical Case Reports.<\/p>\n
The publication reports findings from nine patients who received autologous Natural Killer (NK) cell infusions produced using the Company\u2019s in-house developed culture protocol. Natural Killer (NK) cells are a type of immune cell involved in the body\u2019s natural defense against abnormal cells.<\/p>\n
The patients were monitored pre- and post-infusion for hematological parameters, liver function, hypersensitivity reactions, inflammatory markers as well as tumor markers to assess for potential NK cell-induced or any dose-dependent toxic\/adverse reactions. The study provided evidence of clinical tolerability of the autologous NK cells cultured using the Company\u2019s proprietary protocol.<\/p>\n
The clinical case series study was registered with the National Medical Research Register, Ministry of Health Malaysia, with NMRR ID 25-00333-MUM. Data collection and analysis were conducted in accordance with the ethical principles of the Declaration of Helsinki and Malaysian Good Clinical Practice guidelines. The study involved nine nonconsecutive patients who received NK cell infusions at ALPS<\/a> Medical Centre between 2023 and 2024.<\/p>\n Dr. Tham Seng Kong, Chief Executive Officer of Alps Group, stated, \u201cBased on these preliminary observations, our in-house developed NK cells appear to be safe for use. The NK cells also exhibited cytotoxicity toward in vitro cultured and co-incubated cancer cell models; however, this was assessed using pilot cultures rather than as part of batch-release testing.\u201d<\/p>\n A notable aspect of this case series is the Company\u2019s patent-pending, antibody-free culture method (Malaysian patent application no. PI2025002484) which enables cost-effective, large-scale production of highly pure natural killer (NK) cells using basic culture media and autologous plasma. This approach improves the safety profile of NK cells and lowers manufacturing barriers, potentially making advanced immunotherapy more accessible and efficient.<\/p>\n Preliminary case series data supports the safety of this method, positioning Alps Group at the forefront of scalable, next-generation autologous immune cell therapy solutions. Together with preclinical GLP study data, the findings from this study are intended to support the design of future clinical investigations in a broader patient population.<\/p>\n Details of the study and its findings have been peer-reviewed and published in SAGE Open Medical Case Reports, accessible at: <\/p>\n
![\"\"](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/02\/Alps-Group-Inc.png\")